Zoetis announced that the European Commission has granted the company marketing authorization for CircoMax Myco for the active immunization of pigs against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae.
The company claims that CircoMax Myco offers the most durable combination protection in the European market against PCV2 and M. hyopneumoniae Pathogens. This reduces the viral load of PCV2 in blood and lymphoid tissues, fecal excretion of PCV2, lymphoid tissue damage associated with PCV2 infection, and lung damage associated with M. hyopneumoniae infections.
Protection of pigs has been demonstrated against porcine circovirus genotypes 2a, 2b and 2d and lasts for at least 23 weeks after vaccination in fattening pigs for PCV2 and M. hyopneumoniae.
Monica Balasch, Director of Global Biologics Development at Zoetis, said: “Porcine circovirus type 2 has demonstrated high rates of mutation and recombination and is known to evolve rapidly in Europe and around the world. Commercial PCV2 vaccines have been effective in controlling clinical disease, but there is a growing genetic gap between field viruses and vaccines. Until now, all vaccines in Europe were based on a single genotype, PCV2a, while today the most widespread viruses belong to other genotypes: PCV2b and especially PCV2d.
“We believe there is a need for new vaccines, such as CircoMax Myco which includes two genotypes of PCV2 for wider coverage. We found excellent results showing reduced loss of body weight gain in field trials in the EU. This innovative single dose vaccine is a new tool for veterinarians and producers who can improve their PCV2 and M. hyopneumoniae control programs, in particular in the face of infections with several genotypes by PCV2. “
Alvaro Aldaz, Global Business Development Director, Pork, Zoetis, said: “For many years, intensive vaccination has contributed to selective pressure and the emergence of new genotypes of PCV2. European pig farms are often infected with more than one genotype and subclinical diseases are common. Commercial vaccines are all based on the PCV2a genotype while CircoMax Myco is the first vaccine that includes two PCV2 genotypes (a and b), and the M. hyopneumoniae purified fraction. It is formulated with MetaStim for active immunization, which gives 23 weeks of protection against these threats. “
CircoMax Myco contains an inactivated recombinant chimeric porcine circovirus type 1 containing the protein of porcine circovirus type 2a open reading frame 2 (ORF2), an inactivated recombinant chimeric porcine circovirus type 1 containing the ORF2 protein of porcine circovirus type 2b and inactivated Mycoplasma hyopneumoniae, strain P-5722-3.
While you’re here, take a moment to view our latest vacancies for vets.